| News Updates |
 |
Antiretroviral Medications and Initial Therapy
National HIV Curriculum | May 15, 2026
|
|
Inside the ‘miracle’ drug rollout that could end Aids
Independent | May 6, 2026
|
|
Clinical Guidance for PrEP
CDC | April 30, 2026
|
|
U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
Gilead | April 29, 2026
|
|
State AIDS Drug Assistance Programs Linked to Higher HIV Viral Suppression Rates
IDA | April 28, 2026
|
|
Two-Drug, Single-Tablet Idvynso Receives FDA Approval for HIV-1
IDA | April 24, 2026
|
|
New study reveals few pharmacists prescribe “game-changer” HIV prevention drug
UC Berkeley | April 22, 2026
|
|
Monthly Islatravir Shows Comparable Safety for HIV PrEP, Lowers Lymphocyte Counts
IDA | April 6, 2026
|
|
Viral Suppression and an Undetectable Viral Load
HIV.gov | April 2, 2026
|
|
Existing medication could improve the health of people living with HIV
News Medical | March 23, 2026
|
|
What are the most important things to know about nevirapine?
HIV.gov | March 13, 2026
|
|
Bicillin® L-A Shortage
CDC | March 10, 2026
|
|
Long-acting medications transform HIV prevention, treatment
Healio | March 6, 2026
|
|
A Thorough Analysis of Changing Antibiotic Resistance in Dental Practice: A Narrative Review
Cureus | February 19, 2026
|
|
Drug Interactions with Antiretroviral Medications
National HIV Curriculum | February 12, 2026
|
|
What drugs are contained in the HIV treatment Symtuza?
Drugs.com | February 9, 2026
|
|
First of its kind daily HIV treatment shows promising results
Queen Mary University of London | February 9, 2026
|
|
Drug Database: Emtricitabine / Tenofovir Disoproxil Fumarate
HIV.gov | February 5, 2026
|
|
‘Transformative’ HIV PrEP shot slowly overcomes cost hurdles
The Hill | January 28, 2026
|
|
HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir
Nature | January 27, 2026
|
|
PrEP
CMS.gov | January 20, 2026
|
|
Single-Tablet BIC/LEN Shows Good Results in Phase 3 for HIV Treatment
IDSE | January 16, 2026
|
|
New Once Weekly Investigational Oral Regimen Shows Strong 48 Week Results, Highlighting the Need for Easier HIV Treatment Options
UNC School of Medicine | January 16, 2026
|
|
Prior authorization and HIV medications: Considerations for state policymakers
hivma | January 16, 2026
|
|
Studies show that less frequent, all-injectable treatment for HIV is safe and preferred by adolescents
St Jude Children’s Research Hospital | January 15, 2026
|
|
PrEP Offers Everyone Protection From HIV
Cleveland Clinic | January 14, 2026
|
|
HIV infection Prevention in 2026: How PrEP Can Almost Eliminate Your HIV Risk
Doral Health & Wellness | January 13, 2026
|
|
Charity report urges government to commission PrEP through pharmacies
ThePhamaJournal | January 2, 2026
|
| |
|
